NCT00711997 - Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

December 31, 2010

Conditions

Pancreatic Neoplasms

Interventions

BIOLOGICAL

DTA-H19

Cohort #1: 4 mg DTA-H19 intratumorally 2 times per week for 2 weeks Cohort #2: 8 mg DTA-H19 intratumorally 2 times per week for 2 weeks

Trial Locations (4)

University of Maryland Medical Center, Baltimore

Hadassah University Hospital, Jerusalem

Meir Hospital, Kfar Saba

The Chaim Sheba Medical Center, Tel Litwinsky